KR920701152A - 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산 - Google Patents

당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산

Info

Publication number
KR920701152A
KR920701152A KR1019900701508A KR900701508A KR920701152A KR 920701152 A KR920701152 A KR 920701152A KR 1019900701508 A KR1019900701508 A KR 1019900701508A KR 900701508 A KR900701508 A KR 900701508A KR 920701152 A KR920701152 A KR 920701152A
Authority
KR
South Korea
Prior art keywords
alpha
trifluoromethyl
methyl
acetic acid
benzylamino
Prior art date
Application number
KR1019900701508A
Other languages
English (en)
Inventor
에이. 엉데일 길버트
시 존씨
피. 타니스 스티븐
린 치우-홍
Original Assignee
로버트 에이. 아미테이지
디 업존 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 에이. 아미테이지, 디 업존 캄파니 filed Critical 로버트 에이. 아미테이지
Publication of KR920701152A publication Critical patent/KR920701152A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 하기 일반식(Ⅰ)의 화합물 및 그의 약리학적으로 허용되는 염(이때, R9는 OM이 아니다):
    상기식에서, R은 (a)수소, (b)C1-C10알킬, (c)C2-C10알케닐, (d)C3-C10알키닐, (e)페닐, (f)-C(R6)H-페닐-(R5)b, (g)-SO2-페닐-(R5)b, (h)-C(O)R1, (i)-C(O)OR9, (j)-(CH2)9NR7)(R8), (R (k)-C(O)N(R7)(R8), (l)-(CH2)nHet, (m)-CH2C(O)R4-(CH2)mO(CH2)mCH3, (o)-CH2-(C3-C6)사이클로알킬, (p)C3-C8사이클로알킬이고, 상기식에서, a는 1내지 4, b는 1내지 5, m은 1또는 2, n은 0또는 1, p는 4또는 5, q는 2또는 3이고, 상기식에서, M은 약리학적으로 허용되는 양이온이고, 상기식에서, R1은 (a)수소, (b)C1-C10알킬, (c)C2-10알케닐, (d)C2-C10알키닐, (e)-페닐-(R5)b, (f)-CH2-페닐-(R5)b,이고, 상기식에서, R2는 (a)-CH(R6)-페닐-(R5)b, (b)-CH2-Het, (c)C1-C6알킬, (d)-(CH2)b-페닐-(R5)b이고, 상기식에서, het는 1내지 3개의 헤테로원자(질소, 산소, 황)를 함유하는 5 또는 6원 포화 또는 불포화 고리이고, 상기 헤테로사이클 고리중 어떤 고리가 젠벤고리 또는 또다른 헤테로사이클에 융합된 임의의 비사이클 그룹을 포함하고, 상기식에서, R3는 (a)수소, (b)-C-(O)R1, (c)-C-(O)OR1, (d)-(CH2)b-페닐-(R5)b이고, 상기식에서, R5는 같거나 다르고, (a)수소, (b)할로겐 (c)하이드록시, (d)C1-C10알콕시, (e)C3-C10알케닐옥시, (f)C3-C10알키닐옥시, (g)니트로, (h)아미노, (i)-N(R6)(R7), (j)-NEC(O)R1, (k)-OC(O)R1, (l)-C(O)R1, (m)-트리플루오로메틸, (n)-SO2N(R6)(R7), (o)-SR8, (p)-CN, (r)C1-C4알킬, (s)페닐, (t)-O-CH2-O-이고, 상기식에서, R6은 (a)수소, (b)C1-C10알킬, (c)-C(O)OR, (d)페닐이고, 상기식에서, R7은 (a)수소, (b)C1-C10알킬이고, 상기식에서, R8은 (a)수소, (b)C1-C10알킬, (c)C3-C10알케닐, (d)C3-C10알키닐, (e)페닐-(R5)b, (f)-CH2-페닐-(R5)b, (g)-CH2-het이고, 상기식에서, R9는 (a)수소, (b)하이드록시, (c)OM, (d)-OR8, (e)-N(R6)(R7), (f)페닐인데; 단, n이 0이고, R2가 벤질, 치환된 벤질 또는 알킬 치환된 벤질이고, R이 수소, 벤질 또는 치환된 벤질이고, R1이 수소 또는 메틸이고, R3가 수소 또는 메틸이고, R5가 수소, 벤질옥시 또는 메톡시이고, R6가 수소일때, R4는 벤질옥시카보닐, 에톡시카보닐, 또는 C(O)OM일 수 없으며; n이 1이고 R이 수소 또는 메틸이고, R1이 수소이고, R2가 벤질이고, R3가 수소이고, R5가 수소이고, R6이 수소일때, R4는 카복실 또는 메톡시카보닐일 수 없으며; n이 0이고, R이 수소 또는 4-치환된 벤질이고, R1이 수소 또는 메틸이고, R2가 C1내지 C4알킬이고, R3가 수소 또는 C1내지 C2알킬이고, R5가 수소, 메톡시 또는 벤질옥시이고, R6가 수소일때, R4는 에톡시카보닐, 카복실 또는 프로폭시카보닐일 수 없으며; 또한 일반식(Ⅰ)의 화합물은 하기 화합물이 아니다.
    메틸 알파-[N-메틸-N-3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트, 메틸 알파-[N-메틸-N-3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트 하이드로클로라이드, 알파-[N-메틸-N-3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세트산, 메틸 알파-[3-(트리플루오로메틸)벤질아미노]인돌-3-아세테이트 하이드로클로라이드, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]인돌-3-아세테이트 하이드로클로라이드, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세트산p-페닐펜아실 에스테르, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세트산1-메틸-3-부테닐 에스테르, 2-[3-(트리플루오로메틸)벤질아미노]-2-(1-벤질-3-인돌릴)에탄올, 메틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-아세톡시메틸인돌-3-아세테이트, 메틸 알파-[3-(트리프라루오로메틸)벤질아미노]-1-아세톡시-메틸인돌-3-아세테이트 하이드로크라로라이드, 메틸 알파-(벤질아미노)-인돌-3-아세테이트, 알파-(페닐프로필아미노)-1-벤질인돌-3-아세트산, 메틸 알파-[4-(아미노설포닐)페닐에틸아미노]-인돌-3-아세테이트, 알파-메틸아미노-1-벤질인돌-3-아세트산, 알파-(페닐에틸아미노)-1-벤질인돌-3-아세트산, 알파-[4-(아미노설포닐)페닐에틸아미노]-1-벤질인돌-3-아세트산, 알파-[4-(아미노설포닐)페닐에틸아미노]-1-벤질인돌-3-아세트산, 알파-[(테트라하이드로-2-푸라닐)메틸아미노]-1-벤질인돌-3-아세트산, 알파-[3-(트루플루오로메틸)벤질아미노-벤질인돌-3-아세트산 N,N-디메틸아미드, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-인돌-3-아세테이트, 알파-[(2-푸릴메틸)아미노]-인돌-3-아세트산, 알파-벤질아미노-인돌-3-아세트산, 알파-[3-(트리프루오로메틸벤질아미노]-1-벤질인돌-3-아세트산 아미드, 알파-[4-(메톡시카보닐)벤질아미노]-1-벤질인돌-3-아세트산, 메틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-아세톡시메틸인돌-3-아세테이트, 메틸 알파-[3-(트리프라루오로메틸)벤질아미노]-1-아세톡시메틸인돌-3-아세테이트, 하이드로클로라이드.
  2. 제1항에 있어서, 하기 일반식을 갖는 화합물 :
    상기식에서, R,R1,R2,R5및 R9는 제1항에서 정의한 바와 같다.
  3. 제2항에 있어서, R이 수소 또는 벤질이고, R1이 수소이고, R2가 트리플루오로메틸벤질 또는 푸릴메틸이고, R9가 하이드록시, OR8(이때, R8은 C1-C10알킬이다)및 OM(이때, M은 약리학적으로 허용되는 양이온이다)으로 이루어진 그룹중에서 선택되는 화합물.
  4. 제3항에 있어서, R2가 트리플루오로메틸벤질인 화합물.
  5. 제4항에 있어서, 하기 화합물로 이루어진 그룹중에서 선택된 화합물:
    메틸 알파-[3-(트리플루오로메틸)벤질아미노]-5-메톡시인돌-3-아세테이트, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세트산 하이드로클로라이드, 나트륨 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트, 메틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트 하이드로클로라이드, 알파-[3-(트리플루오로메틸)벤질아미노]-1-페닐인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시 인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-클로로 인돌-3-아세테이트, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트, 옥살레이트(1:1), 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트 하이드로클로라이드, 알파-[3-(트리플루오로메틸)벤질아미노]-인돌-3-아세트산, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-인돌-3-아세테이트, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메틸인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질-아미노]-1-벤질-5-메톡시-6-메틸인돌-3-아세트산, 알파-[3-(트리프라루오로메틸)벤질아미노]-1-벤질-5-메톡시-6-메틸인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5,6-메틸렌-디옥시인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시-6-이소프로필인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시-4-메틸인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시-6-클로로인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-6-메틸인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5,6-디메톡시-인돌-3-아세트산, 에틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시-7-메틸인돌-3-아세트산, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-6-메톡시인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-아세톡시인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-에톡시인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-벤질옥시인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-메톡시인돌-3아세트산,에틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트 말레산염,알파-[3-(트리플루오로메틸)벤질아미노]-인돌-3-아세테이트 하이드로크라로라이드, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질-5-플루오로인돌-3-아세트산,알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌3-아세트산 1-메틸-3-부틸에스테르.
  6. 제5항에 있어서, 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-5-메톡시인돌-3-아세트산인 화합물.
  7. 제5항에 있어서, 알파-[3-(트리플루오로메틸)벤질아미노]-인돌-3-아세트산인 화합물.
  8. 제5항에 있어서, 메틸 알파-[3-(트리플루오로메틸)벤질아미노]-1-벤질인돌-3-아세테이트 하이드로클로라이드인 화합물.
  9. 제3항에 있어서, R2가 푸릴메틸인 화합물.
  10. 제9항에 있어서, 알파-[(2-푸릴메틸)아미노]-1-벤질인돌-3-아세트산인 화합물.
  11. 제2항에 있어서, 하기 화합물로 구성된 그룹중에서 선택된 화합물:
    알파-벤질아미노-1-벤질인돌-3-아세트산, 알파-[(3-피리디닐메틸)아미노]-1-벤질인돌-3-아세트산, 알파-(4-메톡시벤질아미노)-1-벤질인돌-3-아세트산, 알파-[(페닐부틸)아미노]--벤질인돌-3-아세트산, 알파-[(S)-알파-메틸벤질아미노]-1-벤질인돌-3-아세트산 하이드레이트(4:1), 알파-(3-클로로벤질아미노)-1-벤질인돌-3-아세트산, 알파-(2-클로로벤질아미노)-1-벤질인돌-3-아세트산, 알파-[(2-티에닐메틸)아미노]-1-벤질인돌-3-아세트산, 알파-(3-플루오로벤질아미노)-1-벤질인돌-3-아세트산, 알파-(4-플루오로벤질아미노)-1-벤질인돌-3-아세트산, 알파-(3-메톡시벤질아미노)-1-벤질인돌-3-아세트산, 알파-(3-메톡시벤질아미노)-1-벤질인돌-3-아세트산, 알파-(3,4-디클로로벤질아미노)-1-벤질인돌-3-아세트산, 알파-(디페필메틸아미노)-인돌-3-아세트산 하이드레이트(1:0:7).
  12. 제1항에 있어서, 하기 일반식을 갖는 화합물:
    상기식에서, R,R1,R2,R3,R4,R5및 R6은 제1항에서 정의한 바와 같다.
  13. 제12항에 있어서, 하기 화합물로 이루어진 그룹중에서 선택된 화합물:
    N-벤질-1-벤질트립토판 하이드레이트(1:1), N-벤질-1-벤질트립토판 메틸 에스테르, N-(디벤질)-1-벤질트립토판 메틸 에스테르, N-[3-(트리플루오로메틸)벤질]-1-벤질트립토판 하이드레이트(1:1), N-[3-(트리플루오로메틸)벤질]-1-벤질트립토판 메틸 에스테르, N-[3-(트리플루오로메틸)벤질]-1-벤질트립토판 메틸 에스테르, 하이드로크라로라이드, N-(이소프로필)-1-벤질트립토판 메틸 에스테르 하이드로클로라이드, 1-페닐메틸-N-3-(트리플루오로메틸)페닐메틸-L-립리토판-메틸 에스테르, DL-메틸-1-(페닐메틸)-트립토판-메틸 에스테르 모노하이드로 클로라이드, DL-N-1-비스(페닐메틸)트립토판-메틸 에스테르, DL-1-(페닐메틸)-트립토판-N-[[3-(트리플루오로메틸)페닐]-메틸]메틸 에스테르, DL-NH-(1-메틸에틸)1-트립토판-1-(페닐메틸)메틸 에스테르, DL-N-(1-메틸에틸)1-(페닐메틸)-트리톱판 메틸 에스테르, DL-1-(페닐메틸)-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르 모노하이드로클로라이드, DL-N-1-비스(페닐메틸)트립토판, DL-1-(페닐메틸)-N-[[3-(트리플루오로메틸)페닐]-메틸]-트립토판, DL-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르, DL-1-p[(4-클로로페닐)메틸]-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르 DL-1-[(4-클로로페닐)메틸]-N-[[(3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르 DL-N [[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르 모노하이드로클로라이드, DL-[(에틸티오)보닐]-N[[3-(트리플루오로메틸)페닐]메틸]-트립토판, DL-1-[(에틸티오)카보닐]-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 모노하이드로클로라이드, DL-1-[(에톡시카보닐]-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르, DL-1-[(에톡시카보닐]-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판메틸 에스테르 모노하이드로클로라이드, DL-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판, D-1-(페닐메틸)-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르, D-1-(페닐메틸)-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판 메틸 에스테르 모노하이드로클로라이드, (D,L)-1-에틸티오카복시-N-(3-(트리플루오로메틸)페닐)메틸-트립토판 메틸 에스테르, DL-1-[(에톡시카보닐]-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판메틸 에스테르 D-1-(페닐메틸)-N-[[3-(트리플루오로메틸)페닐]메틸]-트립 토판메틸 에스테르, 모노 하이드로 클로라이드, DL-N-[[3-(트리플루오로메틸)페닐]메틸]-트립토판, (D,L)-1-에틸티오카복시-N-(3-(트리플루오로메틸)페닐)메틸-트립토판 메틸 에스테르 HCl.
  14. 제1항에 있어서, 하기 일반식(Ⅰ')을 갖는 화합물:
    상기식에서, R,R1,R2및 R5는 제1항에서 정의한 바와 같다.
  15. 제14항에 있어서, 하기 화합물로 이루어진 그룹중에서 선택된 화합물:
    메틸(±)-알파-(1-페닐메틸-3-인돌릴메틸)아미노-페닐-아세테이트, 메틸(R)-알파-(1-페닐메틸-3-인돌릴메틸)아미노-페닐-아세테이트, 메틸(S)-알파-(1-페닐메틸-3-인돌릴메틸)아미노-페닐-아세테이트, 메틸(±)-알파-(1-페닐메틸-3-인돌릴메틸)아미노-(3-트리플루오로메틸페닐)아세테이트, 메틸(R)-알파-(3-인돌릴메틸)아미노-페닐아세테이트, 메틸(S)-알파-(3-인돌릴메틸)아미노-페닐아세테이트, 메틸(±)-알파-(1-페닐메틸-5-메톡시-3-인돌릴메틸)아미노-(3-트리플루오로메틸페닐)아세테이트, 메틸(±)-알파-(5-메톡시-3-인돌릴메틸)아미노-(3-트리플루오로메틸페닐)아세테이트, 메틸(R)-알파-(1-페닐메틸-5-메톡시-3-인돌릴메틸)아미노-페닐아세테이트, 및 메틸(S)-알파-(1-페닐메틸-5-메톡시-3-인돌릴메틸)아미노-페닐아세테이트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900701508A 1988-11-14 1989-10-27 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산 KR920701152A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27055488A 1988-11-14 1988-11-14
US07/270554 1988-11-14
PCT/US1989/004711 WO1990005721A1 (en) 1988-11-14 1989-10-27 Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents

Publications (1)

Publication Number Publication Date
KR920701152A true KR920701152A (ko) 1992-08-11

Family

ID=23031777

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900701508A KR920701152A (ko) 1988-11-14 1989-10-27 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산

Country Status (6)

Country Link
JP (1) JPH04501722A (ko)
KR (1) KR920701152A (ko)
AU (1) AU4649189A (ko)
CA (1) CA2002415A1 (ko)
IL (1) IL92294A0 (ko)
WO (1) WO1990005721A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100807718B1 (ko) * 2006-10-17 2008-02-28 한국생명공학연구원 인돌 유도체를 유효성분으로 함유하는 대사성 질환 예방 및치료용 약학적 조성물

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2110574A1 (en) * 1991-06-21 1993-01-07 Lawrence I. Kruse Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US5158969A (en) * 1991-08-21 1992-10-27 Neurosearch A/S Indole derivatives as potassium channel blockers
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
US5849764A (en) * 1995-12-14 1998-12-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5780437A (en) * 1995-12-14 1998-07-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6200957B1 (en) 1995-12-14 2001-03-13 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5756507A (en) * 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6197975B1 (en) 1995-12-14 2001-03-06 Merck & Co. , Inc. Antagonists of gonadotropin releasing hormone
ATE319440T1 (de) * 1996-12-23 2006-03-15 Merck & Co Inc Antidiabetische mittel
US6156767A (en) * 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5985901A (en) * 1997-06-05 1999-11-16 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6156772A (en) * 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6004984A (en) * 1997-06-05 1999-12-21 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5981550A (en) * 1997-06-05 1999-11-09 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6159975A (en) * 1998-02-11 2000-12-12 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6025366A (en) * 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6110931A (en) * 1998-04-02 2000-08-29 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6077847A (en) * 1998-04-02 2000-06-20 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6228867B1 (en) 1998-04-02 2001-05-08 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US5985892A (en) * 1998-04-02 1999-11-16 Merck & Co., Ltd. Antagonists of gonadotropin releasing hormone
US5998432A (en) * 1998-04-02 1999-12-07 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3395000A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
JP2003526618A (ja) 1999-03-10 2003-09-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
EP1171135A4 (en) 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOLE COMPOUNDS FOR USE AS GONADOTROPIN RELEASING HORMONE ANTAGONISTS
IL130169A (en) * 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
PE20010580A1 (es) * 1999-09-03 2001-05-25 Takeda Chemical Industries Ltd Composicion farmaceutica para tratar la diabetes
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6620824B2 (en) 2001-04-11 2003-09-16 Merck & Co., Inc. Process for the synthesis of gonadotropin releasing hormone antagonists
WO2005044261A1 (en) * 2003-10-27 2005-05-19 University Of Iowa Research Foundation Melatonin analogue prodrugs
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation ２環化合物
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
DE102008030207A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
US8912220B2 (en) 2009-08-10 2014-12-16 Galenea Pharmaceuticals Compounds and methods of use thereof
GB201411239D0 (en) * 2014-06-25 2014-08-06 Takeda Pharmaceutical Novel compounds
CN114601825B (zh) * 2022-02-18 2023-08-04 复旦大学附属中山医院 一种肠道菌群代谢物吲哚-3-甲醛在防治动脉粥样硬化中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2542869A (en) * 1948-03-19 1951-02-20 Merck & Co Inc N-pyridoxyl-amino acids and process of preparing the same
US3074942A (en) * 1958-01-13 1963-01-22 Geigy Chem Corp alpha-substituted glycine derivatives
NL125657C (ko) * 1963-11-26
GB1080470A (en) * 1963-12-31 1967-08-23 Merck & Co Inc Indole derivatives
EP0031653A1 (en) * 1979-12-19 1981-07-08 Beecham Group Plc N-Substituted alpha-amino acids, processes for making them and pharmaceutical compositions containing them
LU85035A1 (fr) * 1983-10-07 1985-06-19 Midit Derives d'amides d'acides amines,leurs preparation et utilisation ainsi que les compositions contenant ces derives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100807718B1 (ko) * 2006-10-17 2008-02-28 한국생명공학연구원 인돌 유도체를 유효성분으로 함유하는 대사성 질환 예방 및치료용 약학적 조성물

Also Published As

Publication number Publication date
WO1990005721A1 (en) 1990-05-31
IL92294A0 (en) 1990-07-26
JPH04501722A (ja) 1992-03-26
CA2002415A1 (en) 1990-05-14
AU4649189A (en) 1990-06-12

Similar Documents

Publication Publication Date Title
KR920701152A (ko) 당뇨병, 비반증 및 동맥경화증 치료제로 유용한 알파-아미노-인돌-3-세트산
RU2378258C2 (ru) Производные сульфонамида
NO884202L (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater.
ATE236890T1 (de) Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
KR880009928A (ko) N-헤테로시클릭-n(4-피페리딜) 아미드와 이러한 화합물들을 사용하는 방법 및 제약학적 조성물
DE69429984T2 (de) In position 3 durch eine stickstoffgruppe substituierte 1,3-dihydroindol-2-on derivate als vasopressin und/oder ocytocin agonisten und/oder antagonisten
RU2302408C3 (ru) Гидроксаматные производные, применимые в качестве ингибиторов дезацетилазы
ATE149487T1 (de) Säureanilid-derivate und ihre verwendung zur bekämpfung von botrytis
NO308742B1 (no) Morfolintachykininreseptorantagonister og farmasøytisk preparat inneholdende disse
KR920701179A (ko) 살진균성 옥사졸리디논
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TR199802241T2 (ko)
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
DE69017593D1 (de) Substituierte N-(Imidazolyl)alkyl-alanin-Derivate.
CA2507657A1 (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
NO911525L (no) Nye 2,9-disubstituerte-4h-pyrido(1,2-a)pyrimidin-4-oner.
DE69839753D1 (de) 2-(Arylphenyl)amino-imidazolin-Derivate
KR900016212A (ko) 피리딜티아졸리딘 카복스아미드 유도체 및 이의 중간체, 및 이들의 제조방법
DE69510802D1 (de) N-[2-(pyrrolidinyl-1)-1-phenylethyl] acetamide als kappa rezeptor agonisten
KR880008999A (ko) 3-아릴-5-알킬티오-4h-1,2,4-트리아졸
KR927003564A (ko) 크로몬 유도체 및 이 화합물을 유효성분으로 하는 아르도스 리덕타제 저해제
KR900701262A (ko) 췌장염 등에 대한 치료제
KR900011764A (ko) 치환된 벤조[b]피란, 이의 제조방법, 이의 용도 및 이들 화합물을 기본으로 하는 약제학적 제제
KR870000305A (ko) 신규의 화학적 화합물의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application